{
    "clinical_study": {
        "@rank": "60595", 
        "brief_summary": {
            "textblock": "To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human\n      anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo\n      plus active primary treatment in AIDS patients with newly diagnosed and relapsed CMV\n      retinitis.\n\n      Ganciclovir and foscarnet are used for treatment of CMV retinitis, but cause hematologic\n      toxicity and nephrotoxicity, respectively. Despite continued maintenance therapy with these\n      drugs, relapse occurs in 85 percent of patients within 4 months. Studies suggest that MSL\n      109, a human monoclonal antibody, when given with either ganciclovir or foscarnet, may\n      increase initial response and prolong time to progression in patients with CMV retinitis."
        }, 
        "brief_title": "A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)", 
        "completion_date": {
            "#text": "August 1998", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cytomegalovirus Retinitis", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Retinitis", 
                "Cytomegalovirus Retinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Ganciclovir and foscarnet are used for treatment of CMV retinitis, but cause hematologic\n      toxicity and nephrotoxicity, respectively. Despite continued maintenance therapy with these\n      drugs, relapse occurs in 85 percent of patients within 4 months. Studies suggest that MSL\n      109, a human monoclonal antibody, when given with either ganciclovir or foscarnet, may\n      increase initial response and prolong time to progression in patients with CMV retinitis.\n\n      Patients are randomized to receive either MSL 109 or placebo every 2 weeks as supplemental\n      therapy to primary CMV treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication: Required:\n\n          -  Primary CMV treatment.\n\n        Patients must have:\n\n          -  AIDS.\n\n          -  Active CMV retinitis.\n\n          -  At least one photographable lesion of one-quarter or more optic disc area in size.\n\n          -  Undergoing primary treatment for CMV retinitis that is not contraindicated with MSL\n             109.\n\n          -  Visual acuity in at least one eye of 3 or more letters on Early Treatment Diabetic\n             Retinopathy Study ( ETDRS ) chart at 1 meter distance ( Snellen equivalent 5/200 ).\n             Note:\n\n          -  Exceptions may be made if visual acuity impairment is possibly reversible and there\n             is at least light perception in that eye.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Retinal detachment not scheduled for surgical repair.\n\n          -  Media opacity that precludes visualization of the fundus.\n\n          -  Active medical problems sufficient to hinder study compliance.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  IVIG.\n\n          -  CMV immune globulin ( CMVIG ).\n\n          -  Interferon alpha.\n\n          -  Interferon gamma.\n\n          -  Interleukin-2 ( IL-2 ).\n\n        Drug or alcohol abuse sufficient to hinder study compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "300", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000836", 
            "org_study_id": "ACTG 294"
        }, 
        "intervention": {
            "intervention_name": "Sevirumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "Antibodies, Monoclonal", 
            "Cytomegalovirus Retinitis"
        ], 
        "lastchanged_date": "October 24, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "920930946"
                    }, 
                    "name": "UCSD - Shiley Eye Ctr / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "900957003"
                    }, 
                    "name": "UCLA - Jules Stein Eye Institute / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "UCSF - San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "212879217"
                    }, 
                    "name": "Johns Hopkins Hosp / SOCA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "New York Univ Med Ctr / SOCA"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000836"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }, 
    "geocoordinates": {
        "Johns Hopkins Hosp / SOCA": "39.29 -76.612", 
        "New York Univ Med Ctr / SOCA": "40.714 -74.006", 
        "Northwestern Univ / SOCA": "41.878 -87.63", 
        "UCLA - Jules Stein Eye Institute / SOCA": "34.052 -118.244", 
        "UCSD - Shiley Eye Ctr / SOCA": "32.839 -117.277", 
        "UCSF - San Francisco Gen Hosp": "37.775 -122.419"
    }
}